Sleep and antidepressant treatment

Current Pharmaceutical Design

Volumn 18, Issue 32, 2012, Pages 5802-5817

  Wichniak, Adam ^a   Wierzbicka, Aleksandra ^a   Jernajczyk, Wojciech ^a  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Antidepressants; Depression; Effects on sleep; Primary insomnia; Sleep

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; REBOXETINE; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRIMIPRAMINE; VENLAFAXINE;

ANTIDEPRESSANT ACTIVITY; CIRCADIAN RHYTHM; DEPRESSION; HUMAN; INSOMNIA; MAINTENANCE THERAPY; PRESCRIPTION; PRIORITY JOURNAL; REM SLEEP; REVIEW; SEDATION; SLEEP; SLEEP DISORDER; SLEEP PARAMETERS; SLEEP PATTERN; SLOW WAVE SLEEP; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM;

ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; HYPNOTICS AND SEDATIVES; RISK FACTORS; SLEEP; SLEEP DISORDERS; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 84867724807     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212803523608     Document Type: Review

References (175)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., text rev. Washington, DC, 2000.
2. Abad VC, Guilleminault C. Sleep and psychiatry. Dialogues Clin Neurosci 2005; 7: 291-303.
3. Kaplan KA, Harvey AG. Hypersomnia across mood disorders: a review and synthesis. Sleep Med Rev 2009; 13: 275-85.
4. Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: A meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord 2011; 135: 10-9.
5. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989; 262: 1479-84.
6. McCall WV, Blocker JN, D'Agostino R, Jr., et al. Insomnia severity is an indicator of suicidal ideation during a depression clinical trial. Sleep Med 2010; 11: 822-7.
7. Thase ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 1999; 60 (Suppl 17): 28-31.
8. Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res 2003; 37: 9-15.
9. Jindal RD, Thase ME. Treatment of insomnia associated with clinical depression. Sleep Med Rev 2004; 8: 19-30.
10. Le Bon O. Contribution of sleep research to the development of new antidepressants. Dialogues Clin Neurosci 2005; 7: 305-13.
11. Janowsky DS, el-Yousef MK, Davis JM, Sekerke HJ. A cholinergic-adrenergic hypothesis of mania and depression. Lancet 1972; 2: 632-5.
12. Lanni C, Govoni S, Lucchelli A, Boselli C. Depression and antidepressants: molecular and cellular aspects. Cell Mol Life Sci 2009; 66: 2985-3008.
13. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477-501.
14. Holsboer F, Ising M. Stress hormone regulation: biological role and translation into therapy. Annu Rev Psychol 2010; 61: 81-11.
15. Borbely AA. The S-deficiency hypothesis of depression and the two-process model of sleep regulation. Pharmacopsychiatry 1987; 20: 23-9.
16. Germain A, Kupfer DJ. Circadian rhythm disturbances in depression. Hum Psychopharmacol 2008; 23: 571-85.
17. Monteleone P, Maj M. The circadian basis of mood disorders: recent developments and treatment implications. Eur Neuropsychopharmacol 2008; 18: 701-11.
18. Kupfer DJ, Foster FG. Interval between onset of sleep and rapideye-movement sleep as an indicator of depression. Lancet 1972; 2: 684-6.
19. Hobson JA, McCarley RW, Wyzinski PW. Sleep cycle oscillation: reciprocal discharge by two brainstem neuronal groups. Science 1975; 189: 55-8.
20. McCarley RW. REM sleep and depression: common neurobiological control mechanisms. Am J Psychiatry 1982; 139: 565-70.
21. Murillo-Rodriguez E, rias-Carrion O, Sanguino-Rodriguez K, Gonzalez-Arias M, Haro R. Mechanisms of sleep-wake cycle modulation. CNS Neurol Disord Drug Targets 2009; 8: 245-53.
22. Kupfer DJ. REM latency: a psychobiologic marker for primary depressive disease. Biol Psychiatry 1976; 11: 159-74.
23. Vogel GW, Buffenstein A, Minter K, Hennessey A. Drug effects on REM sleep and on endogenous depression. Neurosci Biobehav Rev 1990; 14: 49-63.
24. Benca RM, Obermeyer WH, Thisted RA, Gillin JC. Sleep and psychiatric disorders. A meta-analysis. Arch Gen Psychiatry 1992; 49: 651-68.
25. Armitage R, Rush AJ, Trivedi M, Cain J, Roffwarg HP. The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacology 1994; 10: 123-7.
26. Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, et al. Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26:249-60.
27. Schmid DA, Wichniak A, Uhr M, et al. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology 2006; 31: 832-44.
28. Nickel T, Sonntag A, Schill J, et al. Clinical and neurobiological effects of tianeptine and paroxetine in major depression. J Clin Psychopharmacol 2003; 23: 155-68.
29. Ising M, Horstmann S, Kloiber S, et al. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker? Biol Psychiatry 2007; 62: 47-54.
30. Steiger A. Neurochemical regulation of sleep. J Psychiatr Res 2007; 41: 537-52.
31. Held K, Kunzel H, Ising M, et al. Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression. J Psychiatr Res 2004; 38: 129-36.
32. Rodenbeck A, Cohrs S, Jordan W, Huether G, Ruther E, Hajak G. The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebocontrolled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks. Psychopharmacology (Berl) 2003; 170: 423-8.
33. Borbely AA. A two process model of sleep regulation. Hum Neurobiol 1982; 1: 195-204.
34. de Bodinat C, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, Millan MJ. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010; 9: 628-42.
35. Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 2011; 378: 621-31.
36. Quera Salva MA, Hartley S, Barbot F, Alvarez JC, Lofaso F, Guilleminault C. Circadian rhythms, melatonin and depression. Curr Pharm Des 2011; 17: 1459-70.
37. Germain A, Kupfer DJ. Circadian rhythm disturbances in depression. Hum Psychopharmacol 2008; 23: 571-85.
38. Gorwood P. Depression and circadian rhythm disturbances. Medicographia 2007; 29: 22-7.
39. Monteleone P, Maj M. The circadian basis of mood disorders: recent developments and treatment implications. Eur Neuropsychopharmacol 2008; 18: 701-11.
40. Hajak G, Landgrebe M. Time and depression: when the internal clock does not work. Medicographia 2010; 32: 146-51.
41. Frank E, Swartz HA, Boland E. Interpersonal and social rhythm therapy: an intervention addressing rhythm dysregulation in bipolar disorder. Dialogues Clin Neurosci 2007; 9: 325-32.
42. Mendlewicz J. Sleep disturbances: core symptoms of major depressive disorder rather than associated or comorbid disorders. World J Biol Psychiatry 2009; 10: 269-75.
43. Rechtschaffen A, Kales A. A Manual of Standardized Terminology and Scoring System for Sleep Stages of Human Subjects. Los Angeles, BIS/BRI, UCLA, 1968.
44. Iber C, Ancoli-Israel S, Chesson A, Quan S. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications. Westchester, IL, American Academy of Sleep Medicine, 2007.
45. Lauer CJ, Riemann D, Wiegand M, Berger M. From early to late adulthood. Changes in EEG sleep of depressed patients and healthy volunteers. Biol Psychiatry 1991; 29: 979-93.
46. Wichniak A, Riemann D, Kiemen A, Voderholzer U, Jernajczyk W. Comparison between eye movement latency and REM sleep parameters in major depression. Eur Arch Psychiatry Clin Neurosci 2000; 250: 48-52.
47. Wichniak A, Antczak J, Wierzbicka A, Jernajczyk W. Alterations in pattern of rapid eye movement activity during REM sleep in depression. Acta Neurobiol Exp (Wars) 2002; 62: 243-50.
48. Pillai V, Kalmbach DA, Ciesla JA. A meta-analysis of electroencephalographic sleep in depression: evidence for genetic biomarkers. Biol Psychiatry 2011; 70: 912-9.
49. Lauer CJ, Schreiber W, Holsboer F, Krieg JC. In quest of identifying vulnerability markers for psychiatric disorders by all-night polysomnography. Arch Gen Psychiatry 1995; 52: 145-53.
50. Modell S, Ising M, Holsboer F, Lauer CJ. The Munich Vulnerability Study on Affective Disorders: stability of polysomnographic findings over time. Biol Psychiatry 2002; 52: 430-7.
51. Modell S, Ising M, Holsboer F, Lauer CJ. The Munich vulnerability study on affective disorders: premorbid polysomnographic profile of affected high-risk probands. Biol Psychiatry 2005; 58: 694-9.
52. Battaglia M, Ferini SL, Bertella S, Bajo S, Bellodi L. First-cycle REM density in never-depressed subjects with borderline personality disorder. Biol Psychiatry 1999; 45: 1056-8.
53. Steiger A, Kimura M. Wake and sleep EEG provide biomarkers in depression. J Psychiatr Res 2010; 44: 242-52.
54. Modell S, Huber J, Holsboer F, Lauer CJ. The Munich Vulnerability Study on Affective Disorders: risk factors for unipolarity versus bipolarity. J Affect Disord 2003; 74: 173-84.
55. Clark C, Dupont R, Golshan S, Gillin JC, Rapaport MH, Kelsoe JR. Preliminary evidence of an association between increased REM density and poor antidepressant response to partial sleep deprivation. J Affect Disord 2000; 59: 77-83.
56. Clark CP, Gillin JC, Golshan S, et al. Increased REM sleep density at admission predicts relapse by three months in primary alcoholics with a lifetime diagnosis of secondary depression. Biol Psychiatry 1998; 43: 601-7.
57. Keshavan MS, Reynolds CF, Montrose D, Miewald J, Downs C, Sabo EM. Sleep and suicidality in psychotic patients. Acta Psychiatr Scand 1994; 89: 122-5.
58. Rao U, Dahl RE, Ryan ND, et al. The relationship between longitudinal clinical course and sleep and cortisol changes in adolescent depression. Biol Psychiatry 1996; 40: 474-84.
59. Thase ME, Buysse DJ, Frank E, et al. Which depressed patients will respond to interpersonal psychotherapy? The role of abnormal EEG sleep profiles. Am J Psychiatry 1997; 154: 502-9.
60. Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs 2005; 65: 927-47.
61. Reynolds CF, III, Kupfer DJ, Taska LS, Hoch CC, Spiker DG, Sewitch DE et al. EEG sleep in elderly depressed, demented, and healthy subjects. Biol Psychiatry 1985; 20: 431-42.
62. Dykierek P, Stadtmuller G, Schramm P, et al. The value of REM sleep parameters in differentiating Alzheimer's disease from oldage depression and normal aging. J Psychiatr Res 1998; 32: 1-9.
63. Gillin JC, Sutton L, Ruiz C, et al. The cholinergic rapid eye movement induction test with arecoline in depression. Arch Gen Psychiatry 1991; 48: 264-70.
64. Riemann D, Hohagen F, Bahro M, Berger M. Sleep in depression: the influence of age, gender and diagnostic subtype on baseline sleep and the cholinergic REM induction test with RS 86. Eur Arch Psychiatry Clin Neurosci 1994; 243: 279-90.
65. Schreiber W, Lauer CJ, Krumrey K, Holsboer F, Krieg JC. Cholinergic REM sleep induction test in subjects at high risk for psychiatric disorders. Biol Psychiatry 1992; 32: 79-90.
66. Jernajczyk W. Latency of eye movement and other REM sleep parameters in bipolar depression. Biol Psychiatry 1986; 21: 465-72.
67. Borbely AA. New techniques for the analysis of the human sleepwake cycle. Brain Dev 1986; 8: 482-8.
68. Campbell IG. EEG recording and analysis for sleep research. Curr Protoc Neurosci 2009; Chapter 10: Unit10.2.
69. Kupfer DJ, Frank E, McEachran AB, Grochocinski VJ. Delta sleep ratio. A biological correlate of early recurrence in unipolar affective disorder. Arch Gen Psychiatry 1990; 47: 1100-5.
70. Buysse DJ, Frank E, Lowe KK, Cherry CR, Kupfer DJ. Electroencephalographic sleep correlates of episode and vulnerability to recurrence in depression. Biol Psychiatry 1997; 41: 406-18.
71. Nissen C, Feige B, Konig A, Voderholzer U, Berger M, Riemann D. Delta sleep ratio as a predictor of sleep deprivation response in major depression. J Psychiatr Res 2001; 35: 155-63.
72. Kupfer DJ, Coble P, Kane J, Petti T, Conners CK. Imipramine and EEG sleep in children with depressive symptoms. Psychopharmacology (Berl) 1979; 60: 117-23.
73. Lahmeyer HW, Poznanski EO, Bellur SN. EEG sleep in depressed adolescents. Am J Psychiatry 1983; 140: 1150-3.
74. Rao U, Poland RE. Electroencephalographic sleep and hypothalamic-pituitary-adrenal changes from episode to recovery in depressed adolescents. J Child Adolesc Psychopharmacol 2008; 18: 607-13.
75. Goetz RR, Puig-Antich J, Ryan N, Rabinovich H, Ambrosini PJ, Nelson B et al. Electroencephalographic sleep of adolescents with major depression and normal controls. Arch Gen Psychiatry 1987; 44: 61-8.
76. Puig-Antich J, Goetz R, Hanlon C, Davies M, Thompson J, Chambers WJ et al. Sleep architecture and REM sleep measures in prepubertal children with major depression: a controlled study. Arch Gen Psychiatry 1982; 39: 932-9.
77. Taub JM, Hawkins DR, van de Castle RL. Electrographic analysis of the sleep cycle in young depressed patients. Biol Psychol 1978; 7: 203-14.
78. Rush AJ, Erman MK, Giles DE, Schlesser MA, Carpenter G, Vasavada N et al. Polysomnographic findings in recently drug-free and clinically remitted depressed patients. Arch Gen Psychiatry 1986; 43: 878-84.
79. Steiger A, von BU, Herth T, Holsboer F. Sleep EEG and nocturnal secretion of cortisol and growth hormone in male patients with endogenous depression before treatment and after recovery. J Affect Disord 1989; 16: 189-95.
80. Kupfer DJ, Ehlers CL, Frank E, Grochocinski VJ, McEachran AB. EEG sleep profiles and recurrent depression. Biol Psychiatry 1991; 30: 641-55.
81. Jindal RD, Thase ME, Fasiczka AL, al. Electroencephalographic sleep profiles in single-episode and recurrent unipolar forms of major depression: II. Comparison during remission. Biol Psychiatry 2002; 51: 230-6.
82. Spiker DG, Coble P, Cofsky J, Foster FG, Kupfer DJ. EEG sleep and severity of depression. Biol Psychiatry 1978; 13: 485-8.
83. Feinberg M, Gillin JC, Carroll BJ, Greden JF, Zis AP. EEG studies of sleep in the diagnosis of depression. Biol Psychiatry 1982; 17: 305-16.
84. Iovieno N, van NA, Clain A, Baer L, Nierenberg AA. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. Depress Anxiety 2011; 28: 137-44.
85. Hajak G, Cluydts R, Allain H, et al. The challenge of chronic insomnia: is non-nightly hypnotic treatment a feasible alternative? Eur Psychiatry 2003; 18: 201-8.
86. Spielman AJ, Caruso LS, Glovinsky PB. A behavioral perspective on insomnia treatment. Psychiatr Clin North Am 1987; 10: 541-53.
87. Espie CA. Stepped care: a health technology solution for delivering cognitive behavioral therapy as a first line insomnia treatment. Sleep 2009; 32: 1549-58.
88. Jindal RD, Fasiczka AL, Himmelhoch JM, Mallinger AG, Thase ME. Effects of tranylcypromine on the sleep of patients with anergic bipolar depression. Psychopharmacol Bull 2003; 37: 118-26.
89. Landolt HP, de Boer LP. Effect of chronic phenelzine treatment on REM sleep: report of three patients. Neuropsychopharmacology 2001; 25: S63-7.
90. Minot R, Luthringer R, Macher JP. Effect of moclobemide on the psychophysiology of sleep/wake cycles: a neuroelectrophysiological study of depressed patients administered with moclobemide. Int Clin Psychopharmacol 1993; 7: 181-9.
91. Monti JM, Alterwain P, Monti D. The effects of moclobemide on nocturnal sleep of depressed patients. J Affect Disord 1990; 20: 201-8.
92. Steiger A, Benkert O, Holsboer F. Effects of long-term treatment with the MAO-A inhibitor moclobemide on sleep EEG and nocturnal hormonal secretion in normal men. Neuropsychobiology 1994; 30: 101-5.
93. Armitage R. The effects of antidepressants on sleep in patients with depression. Can J Psychiatry 2000; 45: 803-9.
94. Chalon S, Pereira A, Lainey E, Vandenhende F, Watkin JG, Staner L et al. Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects. Psychopharmacology (Berl) 2005; 177: 357-65.
95. Sonntag A, Rothe B, Guldner J, Yassouridis A, Holsboer F, Steiger A. Trimipramine and imipramine exert different effects on the sleep EEG and on nocturnal hormone secretion during treatment of major depression. Depression 1996; 4: 1-13.
96. Suzuki H, Yamadera H, Nakamura S, Endo S. Effects of trazodone and imipramine on the biological rhythm: an analysis of sleep EEG and body core temperature. J Nihon Med Sch 2002; 69: 333-41.
97. Yamadera H, Nakamura S, Suzuki H, Endo S. Effects of trazodone hydrochloride and imipramine on polysomnography in healthy subjects. Psychiatry Clin Neurosci 1998; 52: 439-43.
98. Luthringer R, Toussaint M, Schaltenbrand N, et al. A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression. Psychopharmacol Bull 1996; 32: 637-46.
99. Salin-Pascual RJ, Galicia-Polo L, Drucker-Colin R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry 1997; 58: 348-50.
100. Trivedi MH, Rush AJ, Armitage R, Gullion CM, Grannemann BD, Orsulak PJ et al. Effects of fluoxetine on the polysomnogram in outpatients with major depression. Neuropsychopharmacology 1999; 20: 447-59.
101. Sharpley AL, Williamson DJ, Attenburrow ME, Pearson G, Sargent P, Cowen PJ. The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology (Berl) 1996; 126: 50-4.
102. Kupfer DJ, Perel JM, Pollock BG, Nathan RS, Grochocinski VJ, Wilson MJ et al. Fluvoxamine versus desipramine: comparative polysomnographic effects. Biol Psychiatry 1991; 29: 23-40.
103. Wilson SJ, Bell C, Coupland NJ, Nutt DJ. Sleep changes during long-term treatment of depression with fluvoxamine--a home-based study. Psychopharmacology (Berl) 2000; 149: 360-5.
104. Jindal RD, Friedman ES, Berman SR, Fasiczka AL, Howland RH, Thase ME. Effects of sertraline on sleep architecture in patients with depression. J Clin Psychopharmacol 2003; 23: 540-8.
105. van Bemmel AL, van den Hoofdakker RH, Beersma DG, Bouhuys AL. Changes in sleep polygraphic variables and clinical state in depressed patients during treatment with citalopram. Psychopharmacology (Berl) 1993; 113: 225-30.
106. Nofzinger EA, Reynolds CF, III, Thase ME, Frank E, Jennings JR, Fasiczka AL et al. REM sleep enhancement by bupropion in depressed men. Am J Psychiatry 1995; 152: 274-6.
107. Schittecatte M, Dumont F, Machowski R, Cornil C, Lavergne F, Wilmotte J. Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology 2002; 46: 197-201.
108. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71: 1259-72.
109. Borbely AA, Mattmann P, Loepfe M, Strauch I, Lehmann D. Effect of benzodiazepine hypnotics on all-night sleep EEG spectra. Hum Neurobiol 1985; 4: 189-94.
110. Landolt HP, Finelli LA, Roth C, Buck A, Achermann P, Borbely AA. Zolpidem and sleep deprivation: different effect on EEG power spectra. J Sleep Res 2000; 9: 175-83.
111. Trachsel L, Dijk DJ, Brunner DP, Klene C, Borbely AA. Effect of zopiclone and midazolam on sleep and EEG spectra in a phaseadvanced sleep schedule. Neuropsychopharmacology 1990; 3: 11-8.
112. Parrino L, Spaggiari MC, Boselli M, Di Giovanni G, Terzano MG. Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia. Psychopharmacology (Berl) 1994; 116: 389-95.
113. Suzuki H, Yamadera H, Nakamura S, Endo S. Effects of trazodone and imipramine on the biological rhythm: an analysis of sleep EEG and body core temperature. J Nippon Med Sch 2002; 69: 333-41.
114. Winokur A, DeMartinis NA, III, McNally DP, Gary EM, Cormier JL, Gary KA. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry 2003; 64: 1224-9.
115. Kim SW, Shin IS, Kim JM, Park KH, Youn T, Yoon JS. Factors potentiating the risk of mirtazapine-associated restless legs syndrome. Hum Psychopharmacol 2008; 23: 615-20.
116. Rottach KG, Schaner BM, Kirch MH, et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res 2008; 43: 70-5.
117. Ellison JM, Stanziani P. SSRI-associated nocturnal bruxism in four patients. J Clin Psychiatry 1993; 54: 432-4.
118. Wolf R, Dykierek P, Gattaz WF, et al. Differential effects of trimipramine and fluoxetine on sleep in geriatric depression. Pharmacopsychiatry 2001; 34: 60-5.
119. Quera-Salva MA, Lemoine P, Guilleminault C. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients. Hum Psychopharmacol 2010; 25: 222-9.
120. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 2010; 24: 1577-601.
121. Espie CA. Stepped care: a health technology solution for delivering cognitive behavioral therapy as a first line insomnia treatment. Sleep 2009; 32: 1549-58.
122. Hajak G. New paradigms in the pharmacological treatment of insomnia. Sleep Med 2006; 7: S20-6.
123. Wiegand MH. Antidepressants for the treatment of insomnia: a suitable approach? Drugs 2008; 68: 2411-7.
124. Richey SM, Krystal AD. Pharmacological advances in the treatment of insomnia. Curr Pharm Des 2011; 17: 1471-75.
125. Ancoli-Israel S, Richardson GS, Mangano RM, Jenkins L, Hall P, Jones WS. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med 2005; 6: 107-13.
126. Erman M, Guiraud A, Joish VN, Lerner D. Zolpidem extendedrelease 12.5 mg associated with improvements in work performance in a 6-month randomized, placebo-controlled trial. Sleep 2008; 31: 1371-8.
127. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003; 26: 793-9.
128. Mendelson WB, Roth T, Cassella J, et al. The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. Sleep Med Rev 2004; 8: 7-17.
129. Riemann D, Spiegelhalder K, Feige B, et al. The hyperarousal model of insomnia: a review of the concept and its evidence. Sleep Med Rev 2010; 14: 19-31.
130. Wichniak A, Brunner H, Ising M, Pedrosa GF, Holsboer F, Friess E. Impaired hypothalamic-pituitary-adrenocortical (HPA) system is related to severity of benzodiazepine withdrawal in patients with depression. Psychoneuroendocrinology 2004; 29: 1101-8.
131. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005; 66: 469-76.
132. Weber J, Siddiqui MA, Wagstaff AJ, McCormack PL. Low-dose doxepin: in the treatment of insomnia. CNS Drugs 2010; 24: 713-20.
133. Wichniak A, Wierzbicka A, Jernajczyk W. Patients with insomnia and subthreshold depression show marked worsening of insomniaafter discontinuation of sleep promoting medication. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1671-6.
134. Zavesicka L, Brunovsky M, Horacek J, et al. Trazodone improves the results of cognitive behaviour therapy of primary insomnia in non-depressed patients. Neuro Endocrinol Lett 2008; 29: 895-901.
135. Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999; 281: 991-9.
136. Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia. Hum Psychopharmacol Clin Exp 1998; 13: 191-8.
137. Hohagen F, Montero RF, Weiss E, et al. Treatment of primary insomnia with trimipramine: an alternative to benzodiazepine hypnotics? Eur Arch Psychiatry Clin Neurosci 1994; 244: 65-72.
138. Riemann D, Voderholzer U, Cohrs S, et al. Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. Pharmacopsychiatry 2002; 35: 165-74.
139. Nowell PD, Reynolds CF, III, Buysse DJ, Dew MA, Kupfer DJ. Paroxetine in the treatment of primary insomnia: preliminary clinical and electroencephalogram sleep data. J Clin Psychiatry 1999; 60: 89-95.
140. Jernajczyk W, Soba ska A, Wierzbicka A, Wichniak A, Szatkowska E. The therapy of primary insomnia with citalopram. J Sleep Res 2006; 15 (Suppl 1): 154.
141. Warner MD, Peabody CA, Whiteford HA, Hollister LE. Trazodone and priapism. J Clin Psychiatry 1987; 48: 244-5.
142. Friedmann PD, Herman DS, Freedman S, Lemon SC, Ramsey S, Stein MD. Treatment of sleep disturbance in alcohol recovery: a national survey of addiction medicine physicians. J Addict Dis 2003; 22: 91-103.
143. Owens JA, Rosen CL, Mindell JA, Kirchner HL. Use of pharmacotherapy for insomnia in child psychiatry practice: A national survey. Sleep Med 2010; 11: 692-700.
144. Dording CM, Mischoulon D, Petersen TJ, et al. The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. Ann Clin Psychiatry 2002; 14: 143-7.
145. Reeves RR, Bullen JA. Serotonin syndrome produced by paroxetine and low-dose trazodone. Psychosomatics 1995; 36: 159-60.
146. Dimellis D. Serotonin syndrome produced by a combination of venlafaxine and mirtazapine. World J Biol Psychiatry 2002; 3: 167.
147. Benazzi F. Serotonin syndrome with mirtazapine-fluoxetine combination. Int J Geriatr Psychiatry 1998; 13: 495-6.
148. Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007; 30: 959-68.
149. Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T. Longterm efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 2008; 31: 79-90.
150. Dijk DJ. Slow-wave sleep deficiency and enhancement: implications for insomnia and its management. World J Biol Psychiatry 2010; 11 (Suppl 1): 22-8.
151. Voderholzer U, Riemann D, Hornyak M, et al. A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects. Eur Arch Psychiatry Clin Neurosci 2001; 251: 117-23.
152. Thase ME, Murck H, Post A. Clinical relevance of disturbances of sleep and vigilance in major depressive disorder: a review. Prim Care Companion J Clin Psychiatry 2010; 12: PCC.08m00676.
153. Roccatagliata G, Albano C, Maffini M, Farelli S. Alcohol withdrawal syndrome: treatment with trazodone. Int Pharmacopsychiatry 1980; 15: 105-10.
154. Le Bon O, Murphy JR, Staner L, et al. Double-blind, placebocontrolled study of the efficacy of trazodone in alcohol postwithdrawal syndrome: polysomnographic and clinical evaluations. J Clin Psychopharmacol 2003; 23: 377-83.
155. Parrino L, Spaggiari MC, Boselli M, Di Giovanni G, Terzano MG. Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia. Psychopharmacology (Berl) 1994; 116: 389-95.
156. Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, et al. Insomnia related to dysthymia: polysomnographic and psychometric comparison with normal controls and acute therapeutic trials with trazodone. Neuropsychobiology 2001; 44: 139-49.
157. Petrovic M, Pevernagie D, Van Den NN, Mariman A, Michielsen W, Afschrift M. A programme for short-term withdrawal from benzodiazepines in geriatric hospital inpatients: success rate and effect on subjective sleep quality. Int J Geriatr Psychiatry 1999; 14: 754-60.
158. Warner MD, Dorn MR, Peabody CA. Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. Pharmacopsychiatry 2001; 34: 128-31.
159. Hertzberg MA, Feldman ME, Beckham JC, Davidson JR. Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design. J Clin Psychopharmacol 1996; 16: 294-8.
160. Raffaele R, Rampello L, Vecchio I, Tornali C, Malaguarnera M. Trazodone therapy of the post-stroke depression. Arch Gerontol Geriatr 1996; 22 (Suppl 1): 217-20.
161. Saletu B, Prause W, Anderer P, et al. Insomnia in somatoform pain disorder: sleep laboratory studies on differences to controls and acute effects of trazodone, evaluated by the Somnolyzer 24 x 7 and the Siesta database. Neuropsychobiology 2005; 51: 148-63.
162. Chandrasekaran PK. Employing mirtazapine to aid benzodiazepine withdrawal. Singapore Med J 2008; 49: e166-7.
163. Cruickshank CC, Montebello ME, Dyer KR, et al. A placebocontrolled trial of mirtazapine for the management of methamphetamine withdrawal. Drug Alcohol Rev 2008; 27: 326-33.
164. Cankurtaran ES, Ozalp E, Soygur H, Akbiyik DI, Turhan L, Alkis N. Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer 2008; 16: 1291-8.
165. Theobald DE, Kirsh KL, Holtsclaw E, Donaghy K, Passik SD. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 2002; 23: 442-7.
166. Chung MY, Min KH, Jun YJ, Kim SS, Kim WC, Jun EM. Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Hum Psychopharmacol 2004; 19: 489-94.
167. Lewis JD. Mirtazapine for PTSD nightmares. Am J Psychiatry 2002; 159: 1948-9.
168. Dolev Z. Case series of perimenopausal women with insomnia treated with mirtazapine followed by prolonged-release melatonin add-on and monotherapy. Arch Womens Ment Health 2011; 14: 269-73.
169. Roizenblatt S, Neto NS, Tufik S. Sleep disorders and fibromyalgia. Curr Pain Headache Rep 2011; 15: 347-57.
170. Kerr MM. Amitriptyline in emotional states at the menopause. N Z Med J 1970; 72: 243-5.
171. Thase ME. Depression, sleep, and antidepressants. J Clin Psychiatry 1998; 59 (Suppl 4): 55-65.
172. Hajak G, Rodenbeck A, Voderholzer U, et al. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry 2001; 62: 453-63.
173. Scharf M, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2008; 69: 1557-64.
174. Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 2007; 30: 1555-61.
175. Krystal AD, Durrence HH, Scharf M, et al. Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia. Sleep 2010; 33: 1553-61.